Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

The most important goals for the field of immuno-oncology are to improve the response rate and increase the number of tumor indications that respond to immunotherapy, without increasing adverse side effects. One approach to achieve these goals is to use tumor-directed immunotherapy, i.e., to focus the immune activation to the most relevant part of the immune system. This may improve anti-tumor efficacy as well as reduce immune-related adverse events. Tumor-directed immune activation can be achieved by local injections of immune modulators in the tumor area or by directing the immune modulator to the tumor using bispecific antibodies. In this review, we focus on therapies targeting checkpoint inhibitors and co-stimulatory receptors that can generate tumor-specific T cell responses through localized immune activation.

Detaljer

Författare
  • Peter Ellmark
  • Sara M. Mangsbo
  • Christina Furebring
  • Per Norlén
  • Thomas H. Tötterman
Enheter & grupper
Externa organisationer
  • Alligator Bioscience AB
  • Uppsala universitet, Historiska institutionen
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
  • Immunologi inom det medicinska området

Nyckelord

Originalspråkengelska
Sidor (från-till)1-7
Antal sidor7
TidskriftCancer Immunology and Immunotherapy
Volym66
Utgåva nummer1
Tidigt onlinedatum2016 okt 6
StatusPublished - 2017 jan
PublikationskategoriForskning
Peer review utfördJa